{"id":32402,"date":"2018-08-13T12:00:00","date_gmt":"2018-08-13T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\/"},"modified":"2018-08-13T12:00:00","modified_gmt":"2018-08-13T12:00:00","slug":"positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/de\/news\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\/","title":{"rendered":"Positionierung von Dymista in der Behandlung der allergischen Rhinitis"},"content":{"rendered":"<div class=\"paragraph paragraph--text-columns paragraph-id--1378 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<h2>Rhinology Future Debates Br\u00fcssel 2017<\/h2>\n<p>Debatte zur Positionierung von Dymista, einer nasalen Behandlung bei allergischer Rhinitis. Dymista ist eine symptomatische Behandlung, die ein Antihistaminikum (Azelastin) und ein Kortikosteroid (Fluticasonpropionat) enth\u00e4lt. <\/p>\n<h3>Podiumsteilnehmende<\/h3>\n<p>Dr. David Price, Dr. Glenis Scadding, Dr. Emmanuel Prokopakis, Dr. Wytske Fokkens, Dr. Oliver Pfaar, Dr. Peter Hellings, Dr. Claus Bachert und Dr. Jean Bousquet.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"paragraph paragraph--text-columns paragraph-id--1379 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<div class=\"video-container\"><center><iframe title=\"YouTube-Videoplayer\" src=\"https:\/\/www.youtube.com\/embed\/_GuPUayz1hs?rel=0\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/center><\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Rhinology Future Debates Br\u00fcssel 2017 Debatte zur Positionierung von Dymista, einer nasalen Behandlung bei allergischer Rhinitis. Dymista ist eine symptomatische Behandlung, die ein Antihistaminikum (Azelastin) und ein Kortikosteroid (Fluticasonpropionat) enth\u00e4lt. Podiumsteilnehmende Dr. David Price, Dr. Glenis Scadding, Dr. Emmanuel Prokopakis, Dr. Wytske Fokkens, Dr. Oliver Pfaar, Dr. Peter Hellings, Dr. Claus Bachert und Dr. Jean Bousquet.<\/p>\n","protected":false},"author":1,"featured_media":32422,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[182],"tags":[183,184,185,187,260],"class_list":["post-32402","news","type-news","status-publish","has-post-thumbnail","hentry","category-rhinology-future-debates","tag-rhinologie","tag-debatten","tag-rhinology-future-debates","tag-asthma","tag-allergische-rhinitis-ar"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Positionierung von Dymista in der Behandlung der allergischen Rhinitis - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/de\/news\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Positionierung von Dymista in der Behandlung der allergischen Rhinitis\" \/>\n<meta property=\"og:description\" content=\"Rhinology Future Debates Br\u00fcssel 2017 Debatte zur Positionierung von Dymista, einer nasalen Behandlung bei allergischer Rhinitis. Dymista ist eine symptomatische Behandlung, die ein Antihistaminikum (Azelastin) und ein Kortikosteroid (Fluticasonpropionat) enth\u00e4lt. Podiumsteilnehmende Dr. David Price, Dr. Glenis Scadding, Dr. Emmanuel Prokopakis, Dr. Wytske Fokkens, Dr. Oliver Pfaar, Dr. Peter Hellings, Dr. Claus Bachert und Dr. Jean Bousquet.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/de\/news\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\\\/\",\"name\":\"Positionierung von Dymista in der Behandlung der allergischen Rhinitis - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202017.png\",\"datePublished\":\"2018-08-13T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\\\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202017.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202017.png\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/waehlen-sie-ihren-weg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Positionierung von Dymista in der Behandlung der allergischen Rhinitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Positionierung von Dymista in der Behandlung der allergischen Rhinitis - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/de\/news\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\/","og_locale":"de_DE","og_type":"article","og_title":"Positionierung von Dymista in der Behandlung der allergischen Rhinitis","og_description":"Rhinology Future Debates Br\u00fcssel 2017 Debatte zur Positionierung von Dymista, einer nasalen Behandlung bei allergischer Rhinitis. Dymista ist eine symptomatische Behandlung, die ein Antihistaminikum (Azelastin) und ein Kortikosteroid (Fluticasonpropionat) enth\u00e4lt. Podiumsteilnehmende Dr. David Price, Dr. Glenis Scadding, Dr. Emmanuel Prokopakis, Dr. Wytske Fokkens, Dr. Oliver Pfaar, Dr. Peter Hellings, Dr. Claus Bachert und Dr. Jean Bousquet.","og_url":"https:\/\/www.euforea.org\/de\/news\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","twitter_card":"summary_large_image","twitter_site":"@euforea","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/de\/news\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\/","url":"https:\/\/www.euforea.org\/de\/news\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\/","name":"Positionierung von Dymista in der Behandlung der allergischen Rhinitis - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/de\/news\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/de\/news\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202017.png","datePublished":"2018-08-13T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/de\/news\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/de\/news\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\/"]}]},{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.euforea.org\/de\/news\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202017.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202017.png","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/de\/news\/positionierung-von-dymista-in-der-behandlung-der-allergischen-rhinitis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.euforea.org\/de\/waehlen-sie-ihren-weg\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/de\/news\/"},{"@type":"ListItem","position":3,"name":"Positionierung von Dymista in der Behandlung der allergischen Rhinitis"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/de\/#website","url":"https:\/\/www.euforea.org\/de\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/de\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/de\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.euforea.org\/de\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/news\/32402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/comments?post=32402"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/news\/32402\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/media\/32422"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/media?parent=32402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/categories?post=32402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/tags?post=32402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}